First reported case of a severe immune reaction (cytokine release syndrome) from tislelizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: pleura (malignant pleural effusion)

The cytokine release syndrome initially improved with high-dose steroids, but he developed severe ventilator-associated pneumonia during the steroid taper and died.

PubMed CentralRead more →

Rare small cell lung cancer subtype removed by surgery

Patient Info: Anonymized, Male

Biomarkers: Cytokeratin-negative; focal TTF-1-positive; Napsin A-negative; electron microscopy showed neurosecretory granules; EWSR1 and SS18 rearrangement testing negative

Follow-up scans found no residual, recurrent or metastatic lung cancer, and he was doing well.

PubMed CentralRead more →

Severe kidney injury during pembrolizumab-based treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 70+

Kidney function stabilized during six months of follow-up, and he later began a modified cancer regimen containing SAR408701.

PubMed CentralRead more →

Early kidney injury after first-line treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 70+

Kidney function improved after a short prednisone course, and he later continued cancer care with carboplatin and nab-paclitaxel.

PubMed CentralRead more →

Severe immune-related kidney and lung toxicity during treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 60s

Corticosteroid treatment returned kidney function to baseline, but worsening immune-related lung toxicity led him and his family to choose palliative care.

PubMed CentralRead more →

Kidney inflammation during maintenance treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 50s

Kidney function remained stable during three months of follow-up after prednisone was started for biopsy-confirmed acute tubulointerstitial nephritis.

PubMed CentralRead more →

ECMO-Supported Airway Tumor Removal for Squamous Lung Cancer

Patient Info: Anonymized, Male, 60s

Bronchoscopy at three months found no malignancy, and he remained disease-free one year after hospital discharge.

PubMed CentralRead more →

Immunotherapy and surgery for adenosquamous lung cancer with brain metastases

Patient Info: Anonymized, Female, 70+

Biomarkers: PD-L1 positive; no actionable mutations on next-generation sequencing.

After chemotherapy, 19 cycles of pembrolizumab, and right middle lobectomy, she was off immunotherapy and under observation in remission.

PubMed CentralRead more →

Severe headache during chemotherapy for small-cell lung cancer

Patient Info: Anonymized, Male, 50s

After the regimen change, he completed five chemotherapy cycles, remained free of severe headache, and had improvement in chest pain, cough, and breathing.

PubMed CentralRead more →

Low-dose intrapleural therapy relieved a complex malignant pleural effusion

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: EGFR mutation-negative; ALK alteration-negative; ROS1 alteration-negative.

Metastatic Site: pleura; adrenal gland; bone

The lung cancer had progressed after initial chemotherapy, but rescue treatment of the infected loculated pleural effusion drained 2,000 mL, resolved the collection, and improved her breathing and fever.

PubMed CentralRead more →

Metastatic NRG1-Fusion Lung Cancer Responding to Long-Term Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CD74-NRG1 fusion

Metastatic Site: lungs

As of February 2020, she remained on afatinib 30 mg daily with an ongoing partial response after 27 months.

PubMed CentralRead more →

Recurrent NRG1-Fusion Lung Cancer After Surgery and Immunotherapy

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion

He chose no further treatment after rapid progression on afatinib and died shortly afterward in hospice.

PubMed CentralRead more →

Stage IV Mucinous Lung Cancer Treated With Afatinib and Surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CD74-NRG1 fusion; ALK/ROS1/EGFR/BRAF/KRAS/MET/HER2 wild type; PD-L1 initially not expressed and later 0%-20%

Metastatic Site: bilateral lungs|bone|right adrenal gland

She was alive and receiving treatment after bone and right-adrenal progression at the latest follow-up.

PubMed CentralRead more →

Recurrent Mucinous Lung Cancer With Dose-Dependent Afatinib Responses

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion; PD-L1 not expressed; low tumor mutation burden

Metastatic Site: bilateral lungs

She had progressive lung disease after several targeted-treatment attempts and was receiving paclitaxel with bevacizumab as of February 2020.

PubMed CentralRead more →

More than 10 years living with relapsing extensive-stage small cell lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Chromogranin-positive.

Metastatic Site: pleura; pancreas; left kidney and perinephric region

After five treatment lines and several metastatic relapses over more than 10 years, his latest irinotecan and carboplatin course produced another partial response and he was doing well at the last follow-up.

PubMed CentralRead more →

Late-onset mania revealed advanced small cell lung cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: ACTH-producing tumor with ACTH 776 pg/mL and morning cortisol 206.8 micrograms/dL.

Metastatic Site: right lung; liver

He died a few months after diagnosis from aspiration pneumonia and multiorgan failure in the setting of rapidly deteriorating stage IV small cell lung cancer.

PubMed CentralRead more →

A reversible brain syndrome after chemotherapy for stage IIB lung cancer

Patient Info: Anonymized, Female, 60s | Stage II

Her seizure-related neurological findings resolved during hospitalization, and she was discharged without neurological symptoms after chemotherapy was stopped.

PubMed CentralRead more →

Long-Term Nivolumab Response With Thyroid and Adrenal Side Effects

Patient Info: Anonymized, Male, 50s | Stage IV

Nivolumab remained ongoing at course 82, tumor burden had fallen to one-fifth of baseline, and no disease progression was documented.

PubMed CentralRead more →

Nivolumab-Related Myocarditis and Heart Block in Metastatic Lung Cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: left adrenal gland

He stabilized after high-dose steroids and pacemaker implantation after nivolumab was permanently stopped.

PubMed CentralRead more →

Osimertinib Improved Spinal Cord Metastases in Long-Standing Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Initial surgical specimen: no detected EGFR mutation and ALK-negative. Later pleural-fluid tumor: acquired EGFR T790M mutation with no other detected EGFR mutation.

Metastatic Site: cervical and mediastinal lymph nodes; bone; brain;…

Osimertinib improved neurologic function and kept the lung cancer stable for 14 months; he later died from bacterial pneumonia.

PubMed CentralRead more →

Small Cell Lung Cancer With SIADH in a 45-Year-Old Man Receiving Chemotherapy

Patient Info: Anonymized, male, 40s

After brain and pelvic metastases developed through successive chemotherapy lines, care shifted to a palliative approach and he died approximately 1 year after diagnosis.

PubMed CentralRead more →

Metastatic Lung Adenocarcinoma Complicated by Severe Nivolumab Pneumonitis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Microsatellite stable; low tumor mutation burden; PD-L1 70%

His severe nivolumab-related pneumonitis improved after infliximab.

PubMed CentralRead more →

ERBB2-Mutated Stage III Lung Cancer With Liver Recurrence and Multiple Lines of Therapy

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion

Metastatic Site: liver

After 6 months of disease control on vinorelbine plus trastuzumab, the cancer progressed in all sites and she chose hospice care.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Progression Across Multiple Regimens

Patient Info: Anonymized, male

Biomarkers: ERBB2 V777delinsVGSP mutation

After a brief period of stable disease on cisplatin plus docetaxel, the cancer progressed through erlotinib, gemcitabine and afatinib.

PubMed CentralRead more →